Bayer Natazia’s Bleeding Indication Could Distinguish It In Contraceptive Crowd
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral contraceptive market is highly genericized and safety-conscious. A new indication for Natazia in heavy menstrual bleeding, however, could hold appeal compared to more invasive treatment options.
You may also be interested in...
Charting The Course Of Product Liability: From Yasmin/Yaz To Actos
Bayer’s birth control pills Yasmin and Yaz face the most pharmaceutical product liability actions in federal court followed by Pfizer’s Prempro and GlaxoSmithKline’s Avandia. While GSK has settled the bulk of cases before a single trial, Merck and Novartis are winning Fosamax and Aredia jury verdicts.
New, Existing Players See Opportunity In Crowded Contraceptive Space
With the notable exceptions of Bayer and Johnson & Johnson, big pharma generally does not participate in the contraceptive market. (Merck and Pfizer also are in the market, although their participation occurs on a smaller scale and largely outside the U.S.)
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.